NLS Pharmaceutics Faces Nasdaq Delisting, Seeks Hearing
Ticker: NCEL · Form: 6-K · Filed: Apr 19, 2024 · CIK: 1783036
| Field | Detail |
|---|---|
| Company | Nls Pharmaceutics LTD. (NCEL) |
| Form Type | 6-K |
| Filed Date | Apr 19, 2024 |
| Risk Level | high |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, Nasdaq, regulatory-action
Related Tickers: NLS
TL;DR
Nasdaq wants NLS Pharma out, but they're fighting back with a hearing request.
AI Summary
NLS Pharmaceutics Ltd. announced on April 19, 2024, that it received a staff delisting determination from the Nasdaq Stock Market. The company intends to request a hearing to appeal this decision. This filing incorporates a press release detailing the situation.
Why It Matters
A Nasdaq delisting could significantly impact the liquidity and trading of NLS Pharmaceutics' shares, potentially affecting investor confidence and access to capital.
Risk Assessment
Risk Level: high — The company is facing delisting from a major stock exchange, which poses a significant threat to its market presence and investor accessibility.
Key Players & Entities
- NLS Pharmaceutics Ltd. (company) — The company that received the delisting determination.
- Nasdaq (company) — The stock exchange that issued the delisting determination.
- April 19, 2024 (date) — The date of the press release announcing the delisting determination.
FAQ
What is the specific reason for the Nasdaq staff delisting determination?
The filing does not specify the exact reason for the delisting determination, only that the company received a 'staff delisting determination'.
When did NLS Pharmaceutics receive this determination?
The press release announcing the determination was issued on April 19, 2024.
What action does NLS Pharmaceutics intend to take in response?
NLS Pharmaceutics intends to request a hearing to appeal the delisting determination.
Is this the first time NLS Pharmaceutics has received such a determination?
The filing refers to this as 'Report No. 3' for the month of April 2024, but does not explicitly state if this is the first delisting determination.
Where is NLS Pharmaceutics Ltd. based?
NLS Pharmaceutics Ltd. is based in Zurich, Switzerland.
Filing Stats: 263 words · 1 min read · ~1 pages · Grade level 10.7 · Accepted 2024-04-19 17:16:10
Filing Documents
- ea0204274-6k_nlspharma.htm (6-K) — 11KB
- ea0204274ex99-1_nlspharma.htm (EX-99.1) — 8KB
- 0001213900-24-034569.txt ( ) — 20KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NLS Pharmaceutics Ltd. Date: April 19, 2024 By: /s/ Alexander Zwyer Name: Alexander Zwyer Title: Chief Executive Officer 2